We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Read MoreHide Full Article
Key Takeaways
Neurocrine is the better pick, driven by Ingrezza, Crenessity and Vykat XR growth.
Neurocrine's 2026 sales and EPS are expected to rise 31% and 27%, respectively.
Teva faces generic weakness and $16.6 billion in debt despite growth in key branded drugs.
Both Neurocrine Biosciences (NBIX - Free Report) and Teva Pharmaceuticals (TEVA - Free Report) operate in the pharmaceutical sector, focusing on specialty medicines and treatments for serious health conditions.
NBIX focuses on neuroscience, with growth primarily led by its flagship drug Ingrezza. In contrast, TEVA operates as a global pharmaceutical giant that develops, manufactures and markets both branded and generic/biosimilar drugs.
But which one makes for a better investment pick today? Let's examine the fundamentals of the two stocks to make a prudent choice.
The Case for NBIX
This San Diego-based company’s commercial portfolio currently includes three first-in-class therapies. Neurocrine’s top-line growth is benefiting from strong uptake of Ingrezza, the blockbuster VMAT2 inhibitor approved for two indications — tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD). The drug remains the company’s primary revenue driver and a key pillar of its growth story.
Ingrezza sales rose 17% year over year to $1.4 billion in the first half of 2026, supported by record new prescriptions and double-digit total volume growth. The strong performance prompted management to raise its full-year 2026 Ingrezza sales guidance to $2.83-$2.88 billion from $2.7-$2.8 billion. The midpoint implies approximately 13% year-over-year growth, indicating that Neurocrine expects the drug's commercial momentum to remain solid through the remainder of the year.
The company is also diversifying its revenue base beyond Ingrezza. Crenessity, launched in December 2024 for classic congenital adrenal hyperplasia (CAH), is emerging as a meaningful second growth driver. The drug generated $337 million in sales in the first half of 2026, up about 400% year over year and already exceeding its full-year 2025 sales of $301 million.
The company further expanded its rare-disease portfolio through the $2.9 billion acquisition of Soleno Therapeutics, completed in May 2026. The acquisition added Vykat XR, which is approved to treat hyperphagia in Prader-Willi syndrome (PWS). Following the acquisition, Neurocrine recorded $54 million from the drug’s sales in the second quarter of 2026.
Beyond its marketed products, Neurocrine has a broad pipeline. Its late-stage pipeline includes phase III programs for osavampator in major depressive disorder and direclidine in schizophrenia. The company also has several earlier-stage programs targeting areas including obesity, classic CAH and movement disorders. NBIX expects around 10 clinical study readouts next year.
However, Ingrezza remains a major source of revenues, leaving Neurocrine exposed to competitive pressures. Teva's Austedo and Austedo XR compete directly with Ingrezza in TD and HD chorea. In addition, pricing pressure could increase as a lower negotiated Medicare price for Austedo takes effect in 2027.
Neurocrine is also facing execution risks with Vykat XR, which remains in the early stages of commercialization. Post-marketing serious adverse events have been reported to the FDA, although such reports do not establish that the drug caused the events. NBIX acknowledges that adverse-event or safety concerns could affect market acceptance, prompt regulatory scrutiny or increase treatment discontinuations.
The Case for TEVA
The Israel-based company is one of the world’s largest generic drugmakers in terms of both total and new prescriptions. It enjoys a leading position in the United States, where it commands a share of more than 6% of total U.S. generic prescriptions.
Teva is gradually moving from predominantly traditional small-molecule generic manufacturer to a more diversified player in complex generics and biosimilars. In the past few quarters, the company has launched several successful biosimilars and other high-value complex generics. These include Truxima (biosimilar to Roche’s Rituxan), Simlandi (biosimilar to AbbVie’s Humira), Selarsdi (biosimilar to J&J’s Stelara), Epysqli (biosimilar to AstraZeneca’s Soliris) and Novo Nordisk’s Victoza.
Teva also maintains a diversified portfolio of higher-margin branded and innovative medicines, which are transforming its portfolio mix and financial profile. Its newer products — Austedo, Ajovy (preventive treatment of migraine) and Uzedy (schizophrenia) — are gaining market share and delivering strong top-line growth.
Austedo remains the largest contributor to the franchise, with global sales rising 40% year over year to $696 million in the second quarter. Teva expects Austedo revenues of $2.45-$2.60 billion in 2026. The Austedo franchise got a boost from the launch of Austedo XR, a new once-daily formulation of Austedo. Teva expects Austedo revenues to exceed $3 billion by 2030.
Ajovy is also delivering strong growth, with global revenues increasing 56% year over year to $244 million in the second quarter. Teva expects Ajovy sales of $850-$870 million in 2026 and estimates peak global sales potential of approximately $1 billion. Meanwhile, Uzedy revenues increased 43% to $77 million in the second quarter, with full-year 2026 sales expected to reach $270-$290 million.
However, Teva’s generics business faces a revenue cliff for lenalidomide capsules (the generic version of Bristol-Myers’ Revlimid), due to increased competition in the United States. Global generics revenues are expected to be flat to down in the low single digits in local currency in 2026, excluding the impact of generic Revlimid and the Japan business divestment. This outlook reflects fewer high-value launches, lower seasonal demand for OTC products and increased competition in some markets. The generic market is also highly crowded, as Teva competes with players like Dr. Reddy’s (RDY - Free Report) , Viatris and Sandoz, among others.
The company also faces competitive pressure for some of its key branded drugs. Austedo competes with Ingrezza, while Ajovy faces competition from other CGRP-targeting therapies, including Amgen's Aimovig and Eli Lilly's (LLY - Free Report) Emgality.
In addition, Teva has a high debt load – the company’s consolidated debt (short- plus long-term) was approximately $16.6 billion at the end of June 2026.
How Do Estimates Compare for NBIX & TEVA?
The Zacks Consensus Estimate for Neurocrine’s 2026 sales and EPS implies year-over-year growth of 31% and 27%, respectively. Bottom-line estimates for 2026 have declined during the past 30 days.
Image Source: Zacks Investment Research
For Teva, the Zacks Consensus Estimate for 2026 sales is expected to decline 4% year over year, while EPS estimates are expected to fall 6%. Bottom-line estimates for 2026 have been trending downwards over the past 30 days.
Image Source: Zacks Investment Research
Price Performance and Valuation of NBIX & TEVA
Year to date, shares of Neurocrine have risen 8%, while those of TEVA have increased 18%. In comparison, the industry has climbed 2%, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, NBIX seems to be trading at a premium compared to TEVA, going by the price/earnings (P/E) ratio. Neurocrine’s shares currently trade at 17.61 times forward 12-month earnings, higher than 13.91 for Teva.
Image Source: Zacks Investment Research
NBIX or TEVA: Which Is a Better Pick?
Both Neurocrine and Teva offer investors exposure to growing neuroscience markets and both have important commercial products that could support future growth. However, NBIX appears to be the better pick at present.
Neurocrine offers a stronger near-term growth trajectory, supported by continued Ingrezza momentum, the rapid growth of Crenessity and the addition of Vykat XR. The company also has a broader pipeline, with multiple potential clinical readouts expected in 2027, providing several catalysts that could support the stock’s performance.
In comparison, Teva’s innovative medicines, particularly Austedo, Ajovy and Uzedy, are delivering strong growth. However, weakness in its generics business remains a near-term headwind, while the company’s high debt load adds to its financial risk. These factors could limit the upside potential of the stock despite the strength of its newer branded medicines.
NBIX carries a Zacks Rank #3 (Hold), while TEVA has a Zacks Rank #4 (Sell). This further reinforces NBIX’s more favorable standing in the current investment landscape.
View the Zacks #1 Rank List
Image: Bigstock
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Key Takeaways
Both Neurocrine Biosciences (NBIX - Free Report) and Teva Pharmaceuticals (TEVA - Free Report) operate in the pharmaceutical sector, focusing on specialty medicines and treatments for serious health conditions.
NBIX focuses on neuroscience, with growth primarily led by its flagship drug Ingrezza. In contrast, TEVA operates as a global pharmaceutical giant that develops, manufactures and markets both branded and generic/biosimilar drugs.
But which one makes for a better investment pick today? Let's examine the fundamentals of the two stocks to make a prudent choice.
The Case for NBIX
This San Diego-based company’s commercial portfolio currently includes three first-in-class therapies. Neurocrine’s top-line growth is benefiting from strong uptake of Ingrezza, the blockbuster VMAT2 inhibitor approved for two indications — tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD). The drug remains the company’s primary revenue driver and a key pillar of its growth story.
Ingrezza sales rose 17% year over year to $1.4 billion in the first half of 2026, supported by record new prescriptions and double-digit total volume growth. The strong performance prompted management to raise its full-year 2026 Ingrezza sales guidance to $2.83-$2.88 billion from $2.7-$2.8 billion. The midpoint implies approximately 13% year-over-year growth, indicating that Neurocrine expects the drug's commercial momentum to remain solid through the remainder of the year.
The company is also diversifying its revenue base beyond Ingrezza. Crenessity, launched in December 2024 for classic congenital adrenal hyperplasia (CAH), is emerging as a meaningful second growth driver. The drug generated $337 million in sales in the first half of 2026, up about 400% year over year and already exceeding its full-year 2025 sales of $301 million.
The company further expanded its rare-disease portfolio through the $2.9 billion acquisition of Soleno Therapeutics, completed in May 2026. The acquisition added Vykat XR, which is approved to treat hyperphagia in Prader-Willi syndrome (PWS). Following the acquisition, Neurocrine recorded $54 million from the drug’s sales in the second quarter of 2026.
Beyond its marketed products, Neurocrine has a broad pipeline. Its late-stage pipeline includes phase III programs for osavampator in major depressive disorder and direclidine in schizophrenia. The company also has several earlier-stage programs targeting areas including obesity, classic CAH and movement disorders. NBIX expects around 10 clinical study readouts next year.
However, Ingrezza remains a major source of revenues, leaving Neurocrine exposed to competitive pressures. Teva's Austedo and Austedo XR compete directly with Ingrezza in TD and HD chorea. In addition, pricing pressure could increase as a lower negotiated Medicare price for Austedo takes effect in 2027.
Neurocrine is also facing execution risks with Vykat XR, which remains in the early stages of commercialization. Post-marketing serious adverse events have been reported to the FDA, although such reports do not establish that the drug caused the events. NBIX acknowledges that adverse-event or safety concerns could affect market acceptance, prompt regulatory scrutiny or increase treatment discontinuations.
The Case for TEVA
The Israel-based company is one of the world’s largest generic drugmakers in terms of both total and new prescriptions. It enjoys a leading position in the United States, where it commands a share of more than 6% of total U.S. generic prescriptions.
Teva is gradually moving from predominantly traditional small-molecule generic manufacturer to a more diversified player in complex generics and biosimilars. In the past few quarters, the company has launched several successful biosimilars and other high-value complex generics. These include Truxima (biosimilar to Roche’s Rituxan), Simlandi (biosimilar to AbbVie’s Humira), Selarsdi (biosimilar to J&J’s Stelara), Epysqli (biosimilar to AstraZeneca’s Soliris) and Novo Nordisk’s Victoza.
Teva also maintains a diversified portfolio of higher-margin branded and innovative medicines, which are transforming its portfolio mix and financial profile. Its newer products — Austedo, Ajovy (preventive treatment of migraine) and Uzedy (schizophrenia) — are gaining market share and delivering strong top-line growth.
Austedo remains the largest contributor to the franchise, with global sales rising 40% year over year to $696 million in the second quarter. Teva expects Austedo revenues of $2.45-$2.60 billion in 2026. The Austedo franchise got a boost from the launch of Austedo XR, a new once-daily formulation of Austedo. Teva expects Austedo revenues to exceed $3 billion by 2030.
Ajovy is also delivering strong growth, with global revenues increasing 56% year over year to $244 million in the second quarter. Teva expects Ajovy sales of $850-$870 million in 2026 and estimates peak global sales potential of approximately $1 billion. Meanwhile, Uzedy revenues increased 43% to $77 million in the second quarter, with full-year 2026 sales expected to reach $270-$290 million.
However, Teva’s generics business faces a revenue cliff for lenalidomide capsules (the generic version of Bristol-Myers’ Revlimid), due to increased competition in the United States. Global generics revenues are expected to be flat to down in the low single digits in local currency in 2026, excluding the impact of generic Revlimid and the Japan business divestment. This outlook reflects fewer high-value launches, lower seasonal demand for OTC products and increased competition in some markets. The generic market is also highly crowded, as Teva competes with players like Dr. Reddy’s (RDY - Free Report) , Viatris and Sandoz, among others.
The company also faces competitive pressure for some of its key branded drugs. Austedo competes with Ingrezza, while Ajovy faces competition from other CGRP-targeting therapies, including Amgen's Aimovig and Eli Lilly's (LLY - Free Report) Emgality.
In addition, Teva has a high debt load – the company’s consolidated debt (short- plus long-term) was approximately $16.6 billion at the end of June 2026.
How Do Estimates Compare for NBIX & TEVA?
The Zacks Consensus Estimate for Neurocrine’s 2026 sales and EPS implies year-over-year growth of 31% and 27%, respectively. Bottom-line estimates for 2026 have declined during the past 30 days.
Image Source: Zacks Investment Research
For Teva, the Zacks Consensus Estimate for 2026 sales is expected to decline 4% year over year, while EPS estimates are expected to fall 6%. Bottom-line estimates for 2026 have been trending downwards over the past 30 days.
Image Source: Zacks Investment Research
Price Performance and Valuation of NBIX & TEVA
Year to date, shares of Neurocrine have risen 8%, while those of TEVA have increased 18%. In comparison, the industry has climbed 2%, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, NBIX seems to be trading at a premium compared to TEVA, going by the price/earnings (P/E) ratio. Neurocrine’s shares currently trade at 17.61 times forward 12-month earnings, higher than 13.91 for Teva.
Image Source: Zacks Investment Research
NBIX or TEVA: Which Is a Better Pick?
Both Neurocrine and Teva offer investors exposure to growing neuroscience markets and both have important commercial products that could support future growth. However, NBIX appears to be the better pick at present.
Neurocrine offers a stronger near-term growth trajectory, supported by continued Ingrezza momentum, the rapid growth of Crenessity and the addition of Vykat XR. The company also has a broader pipeline, with multiple potential clinical readouts expected in 2027, providing several catalysts that could support the stock’s performance.
In comparison, Teva’s innovative medicines, particularly Austedo, Ajovy and Uzedy, are delivering strong growth. However, weakness in its generics business remains a near-term headwind, while the company’s high debt load adds to its financial risk. These factors could limit the upside potential of the stock despite the strength of its newer branded medicines.
NBIX carries a Zacks Rank #3 (Hold), while TEVA has a Zacks Rank #4 (Sell). This further reinforces NBIX’s more favorable standing in the current investment landscape.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.